These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12415685)

  • 1. Molecular epidemiology of human cancer risk. Gene-environment interactions and p53 mutation spectrum in human lung cancer.
    Vähäkangas K
    Methods Mol Med; 2003; 74():43-59. PubMed ID: 12415685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.
    Bennett WP; Hussain SP; Vahakangas KH; Khan MA; Shields PG; Harris CC
    J Pathol; 1999 Jan; 187(1):8-18. PubMed ID: 10341702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular epidemiology of lung cancer.
    Spivack SD; Fasco MJ; Walker VE; Kaminsky LS
    Crit Rev Toxicol; 1997 Jul; 27(4):319-65. PubMed ID: 9263643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.
    Kawajiri K; Eguchi H; Nakachi K; Sekiya T; Yamamoto M
    Cancer Res; 1996 Jan; 56(1):72-6. PubMed ID: 8548778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology of human cancer.
    Hussain SP; Harris CC
    Recent Results Cancer Res; 1998; 154():22-36. PubMed ID: 10026991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic characteristics of lung cancer--useful as real' tumor markers?
    Fleischhacker M; Beinert T; Possinger K
    Lung Cancer; 1999 Jul; 25(1):7-24. PubMed ID: 10466858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies.
    Huncharek M; Kupelnick B; Geschwind JF; Caubet JF
    Cancer Lett; 2000 May; 153(1-2):219-26. PubMed ID: 10779652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of individual susceptibility in cancer burden related to environmental exposure.
    Bartsch H; Hietanen E
    Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):569-77. PubMed ID: 8781385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology of human cancer.
    Hussain SP; Harris CC
    Toxicol Lett; 1998 Dec; 102-103():219-25. PubMed ID: 10022257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens.
    Hussain SP; Harris CC
    Mutat Res; 2000 Apr; 462(2-3):311-22. PubMed ID: 10767641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers.
    Gao WM; Romkes M; Siegfried JM; Luketich JD; Keohavong P
    Mol Carcinog; 2006 Nov; 45(11):828-32. PubMed ID: 16865671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions.
    Shields PG; Harris CC
    J Clin Oncol; 2000 Jun; 18(11):2309-15. PubMed ID: 10829052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
    Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic polymorphisms and lung cancer susceptibility: a review.
    Kiyohara C; Otsu A; Shirakawa T; Fukuda S; Hopkin JM
    Lung Cancer; 2002 Sep; 37(3):241-56. PubMed ID: 12234692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms of lung cancer development at its different stages in nuclear industry workers].
    Rusinova GG; Vyazovskaya NS; Azizova TV; Revina VS; Glazkova IV; Generozov EV; Zakharzhevskaya NB; Guryanov MY; Belosokhov MV; Osovets SV
    Arkh Patol; 2015; 77(2):10-15. PubMed ID: 26027393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment.
    Hussain SP; Hofseth LJ; Harris CC
    Lung Cancer; 2001 Dec; 34 Suppl 2():S7-15. PubMed ID: 11720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico p53 mutation hotspots in lung cancer.
    Lewis PD; Parry JM
    Carcinogenesis; 2004 Jul; 25(7):1099-107. PubMed ID: 14729588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
    Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.